Abstract
Clinical infomations on 1, 408 patients-46 with insulin-dependent diabetes mellitus (IDDM) and 1362 with non-insulin-dependent diabetes mellitus (NIDDM)-who visited a diabetes mellitus clinic were registered into using software “CoDiC®”, a modification of “NovoNet®” for outcome reseach. Titers of autoantibodies against glutamic acid decarboxylase (GAD) were measured in all IDDM and 74.3% of NIDDM patients. Those found positive to GAD antibody numbered 45.7% of IDDM and 1.8% of NIDDM patients. Based on this data and a clinical course of GAD antibody positive patients with impaired glucose tolerance, we discuss the clinical significance of measuring GAD antibodies.
